ATL is NOT DCVax-L. While the core biological mechanism of ATL-DC (used in UCLA's trials) and DCVax-L (licensed by NWBO) are mechanistically similar and likely overlap in the patented process of dendritic cell maturation, the patents themselves are not exact duplicates. So UCLA uses a different manufacturing process and has had a decade for refine their formulation. And the PATENT says they are DIFFERENT. I'll believe the patent as that's what stands up in court.
Market Data 
Markets 
AI
